Seres Therapeutics (MCRB) Misses Q2 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
FBR Capital Remains Bullish on Seres Therapeutics (MCRB); Says Sell-Off is 'Overdone'
August 12, 2016 8:01 AM EDTFBR Capital maintained an Outperform rating on Seres Therapeutics (NASDAQ: MCRB), and cut the price target to $23.00 (from $43.00), following the company's recent sell-off.
Analyst Vernon Bernardino commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic... More
